The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Open accessAbstract
BACKGROUND: Biologic agents (also termed biologics or biologicals) are becoming increasingly important in the treatment of immune-mediated diseases. However, the diversity of clinical trials along with the fast pace of publication makes it difficult to determine the level of evidence for the use of a biologic for a given disorder. To address this challenge, we are publishing a series of systematic reviews evaluating the safety and efficacy of B cell-targeting biologics for the treatment of immune-mediated diseases. In this article, we have assessed the safety and efficacy of belimumab, a fully human IgG1 monoclonal antibody targeting the cytokine B cell-activating factor (BAFF). OBJECTIVE: To evaluate belimumab's safety and efficacy for the treatment of immune-mediated disorders compared to placebo, conventional treatment or other biologics. METHODS: The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist guided the reporting of the data. We searched the PubMed database between October 4, 2016, and June 23, 2019, concentrating on immune-mediated disorders. RESULTS: The literature search identified 583 articles. After screening titles and abstracts against the inclusion and exclusion criteria and assessing full texts, 17 articles were finally included in a narrative synthesis. CONCLUSIONS: Belimumab is both safe and effective for the treatment of systemic lupus erythematosus. Results were further promising for the use of belimumab in patients with rheumatoid arthritis and Sjögren's syndrome. Conversely, results using belimumab in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and myasthenia gravis were rather disappointing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Downs, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,683
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Merrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27233 · Cited by 1,409
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease
Masters, S. L., Simon, A., Aksentijevich, I., & Kastner, D. L. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141627 · Cited by 1,065
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Fanouriakis, A., Kostopoulou, M., Cheema, K., Anders, H.-J., Aringer, M., Bajema, I., Boletis, J., Frangou, E., Houssiau, F. A., Hollis, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216924 · Cited by 825
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213277 · Cited by 728
Rituximab for IgG4-related disease: a prospective, open-label trial
Carruthers, M. N., Topazian, M. D., Khosroshahi, A., Witzig, T. E., Wallace, Z. S., Hart, P. A., Deshpande, V., Smyrk, T. C., Chari, S., & Stone, J. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206605 · Cited by 726
Oddis, C. V., Reed, A. M., Aggarwal, R., Rider, L. G., Ascherman, D. P., Levesque, M. C., Barohn, R. J., Feldman, B. M., Harris‐Love, M. O., Koontz, D. C., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37754 · Cited by 701
Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F., Golinski, M. L., Labeille, B., Picard-Dahan, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30070-3 · Cited by 623
Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24699 · Cited by 585
Khosroshahi, A., Bloch, D. B., Deshpande, V., & Stone, J. H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27435 · Cited by 522
Rituximab for the Treatment of IgG4-Related Disease: Lessons From 10 Consecutive Patients
Khosroshahi, A., Carruthers, M. N., Deshpande, V., Unizony, S., Bloch, D. B., & Stone, J. H. (2012) · Medicine · doi:10.1097/md.0b013e3182431ef6 · Cited by 489
Meijer, J. M., Meiners, P. M., Vissink, A., Spijkervet, F. K. L., Abdulahad, W., Kamminga, N., Brouwer, E., Kallenberg, C. G. M., & Bootsma, H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27314 · Cited by 488
Bingham, C. O., Looney, R. J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., Trzaskoma, B., Martin, F., Agarwal, S., & Kelman, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25034 · Cited by 459
Iijima, K., Sako, M., Nozu, K., Mori, R., Tuchida, N., Kamei, K., Miura, K., Aya, K., Nakanishi, K., Ohtomo, Y., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60541-9 · Cited by 451
The BAFF/APRIL system in SLE pathogenesis
Vincent, F. B., Morand, E. F., Schneider, P., & Mackay, F. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.33 · Cited by 448
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Dahan, K., Debiec, H., Plaisier, E., Cachanado, M., Rousseau, A., Wakselman, L., Michel, P.-A., Mihout, F., Dussol, B., Matignon, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040449 · Cited by 439
Dass, S., Bowman, S. J., Vital, E. M., Ikeda, K., Pease, C. T., Hamburger, J., Richards, A., Rauz, S., & Emery, P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083865 · Cited by 431
Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial
Devauchelle-Pensec, V., Mariette, X., Jousse-Joulin, S., Berthelot, J.-M., Perdriger, A., Puéchal, X., Le Guern, V., Sibilia, J., Gottenberg, J.-E., Chiche, L., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1085 · Cited by 429
Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., Doria, A., Hammer, A. E., Kleoudis, C., Groark, J., Bass, D., Fox, N. L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40049 · Cited by 420
Salvi, M., Vannucchi, G., Currò, N., Campi, I., Covelli, D., Dazzi, D., Simonetta, S., Guastella, C., Pignataro, L., Avignone, S., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3014 · Cited by 412
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis
De Vita, S., Quartuccio, L., Isola, M., Mazzaro, C., Scaini, P., Lenzi, M., Campanini, M., Naclerio, C., Tavoni, A., Pietrogrande, M., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34331 · Cited by 405
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Daoussis, D., Liossis, S.-N. C., Tsamandas, A. C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., Karampetsou, M., Yiannopoulos, G., & Andonopoulos, A. P. (2010) · Rheumatology · doi:10.1093/rheumatology/kep093 · Cited by 394
Randomized Controlled Trial of Rituximab in Patients With Graves' Orbitopathy
Stan, M. N., Garrity, J. A., Carranza Leon, B. G., Prabin, T., Bradley, E. A., & Bahn, R. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2572 · Cited by 369
Genomics and the Multifactorial Nature of Human Autoimmune Disease
Cho, J. H., & Gregersen, P. K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100030 · Cited by 354
Emery, P., Deodhar, A., Rigby, W. F., Isaacs, J. D., Combe, B., Racewicz, A. J., Latinis, K., Abud-Mendoza, C., Szczepański, L. J., Roschmann, R. A., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.119933 · Cited by 348
Long-lasting treatment effect of rituximab in MuSK myasthenia
Díaz-Manera, J., Martínez-Hernández, E., Querol, L., Klooster, R., Rojas-García, R., Suárez-Calvet, X., Muñoz-Blanco, J. L., Mazia, C., Straasheijm, K. R., Gallardo, E., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182407982 · Cited by 346
Kappos, L., Hartung, H.-P., Freedman, M. S., Boyko, A., Radü, E. W., Mikol, D. D., Lamarine, M., Hyvert, Y., Freudensprung, U., Plitz, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70028-6 · Cited by 338
Mariette, X., Seror, R., Quartuccio, L., Baron, G., Salvin, S., Fabris, M., Desmoulins, F., Nocturne, G., Ravaud, P., & De Vita, S. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203991 · Cited by 329
Tak, P. P., Rigby, W. F., Rubbert-Roth, A., Peterfy, C. G., van Vollenhoven, R. F., Stohl, W., Hessey, E., Chen, A., Tyrrell, H., & Shaw, T. M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137703 · Cited by 307
Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C. P., Wofsy, D., Babini, A., Lazaro, M., Lucero, E., Merono, C., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205067 · Cited by 306
Zhang, F., Bae, S.-C., Bass, D., Chu, M., Egginton, S., Gordon, D., Roth, D. A., Zheng, J., & Tanaka, Y. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211631 · Cited by 305
Lafayette, R. A., Canetta, P. A., Rovin, B. H., Appel, G. B., Novak, J., Nath, K. A., Sethi, S., Tumlin, J. A., Mehta, K., Hogan, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060640 · Cited by 300
Ginzler, E. M., Wax, S., Rajeswaran, A., Copt, S., Hillson, J., Ramos, E., & Singer, N. G. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3738 · Cited by 284
Erkan, D., Vega, J., Ramón, G., Kozora, E., & Lockshin, M. D. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37759 · Cited by 279
Jones, R. B., Furuta, S., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206404 · Cited by 277
Bowman, S. J., Everett, C. C., O'Dwyer, J. L., Emery, P., Pitzalis, C., Ng, W., Pease, C. T., Price, E. J., Sutcliffe, N., Gendi, N. S. T., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40093 · Cited by 276
Furie, R., Stohl, W., Ginzler, E. M., Becker, M., Mishra, N., Chatham, W., Merrill, J. T., Weinstein, A., McCune, W. J., Zhong, J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2506 · Cited by 263
Zaja, F., Baccarani, M., Mazza, P., Bocchia, M., Gugliotta, L., Zaccaria, A., Vianelli, N., Defina, M., Tieghi, A., Amadori, S., et al. (2010) · Blood · doi:10.1182/blood-2009-07-229815 · Cited by 259
Merrill, J. T., Wallace, D. J., Wax, S., Kao, A., Fraser, P. A., Chang, P., Isenberg, D., & on behalf of the ADDRESS II Investigators (2018) · Arthritis & Rheumatology · doi:10.1002/art.40360 · Cited by 244
Sneller, M. C., Hu, Z., & Langford, C. A. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34322 · Cited by 236
Gérard, L., Bérezné, A., Galicier, L., Meignin, V., Obadia, M., De Castro, N., Jacomet, C., Verdon, R., Madelaine-Chambrin, I., Boulanger, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6732 · Cited by 235
DAVATCHI, F., SHAMS, H., REZAIPOOR, M., SADEGHI‐ABDOLLAHI, B., SHAHRAM, F., NADJI, A., CHAMS‐DAVATCHI, C., AKHLAGHI, M., FAEZI, T., & NADERI, N. (2010) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2010.01546.x · Cited by 229
Keystone, E., Emery, P., Peterfy, C. G., Tak, P. P., Cohen, S., Genovese, M. C., Dougados, M., Burmester, G. R., Greenwald, M., Kvien, T. K., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.085787 · Cited by 227
Tak, P. P., Thurlings, R. M., Rossier, C., Nestorov, I., Dimic, A., Mircetic, V., Rischmueller, M., Nasonov, E., Shmidt, E., Emery, P., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23178 · Cited by 207
Ravani, P., Magnasco, A., Edefonti, A., Murer, L., Rossi, R., Ghio, L., Benetti, E., Scozzola, F., Pasini, A., Dallera, N., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09421010 · Cited by 207
Song, I. ‐., Heldmann, F., Rudwaleit, M., Listing, J., Appel, H., Braun, J., & Sieper, J. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27383 · Cited by 199
Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease
Bower, M., Powles, T., Williams, S., Davis, T. N., Atkins, M., Montoto, S., Orkin, C., Webb, A., Fisher, M., Nelson, M., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-12-200712180-00003 · Cited by 197
Nikoo, Z., Badihian, S., Shaygannejad, V., Asgari, N., & Ashtari, F. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8590-0 · Cited by 192
Rubbert-Roth, A., Tak, P. P., Zerbini, C., Tremblay, J.-L., Carreno, L., Armstrong, G., Collinson, N., Shaw, T. M., & on behalf of the MIRROR Trial Investigators (2010) · Rheumatology · doi:10.1093/rheumatology/keq116 · Cited by 186
Ginzler, E. M., Wallace, D. J., Merrill, J. T., Furie, R. A., Stohl, W., Chatham, W. W., Weinstein, A., McKay, J. D., McCune, W. J., Zhong, Z. J., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.121368 · Cited by 183
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis
Leiper, K., Martin, K., Ellis, A., Subramanian, S., Watson, A. J., Christmas, S. E., Howarth, D., Campbell, F., & Rhodes, J. M. (2011) · Gut · doi:10.1136/gut.2010.225482 · Cited by 178
Gudbrandsdottir, S., Birgens, H. S., Frederiksen, H., Jensen, B. A., Jensen, M. K., Kjeldsen, L., Klausen, T. W., Larsen, H., Mourits-Andersen, H. T., Nielsen, C. H., et al. (2013) · Blood · doi:10.1182/blood-2012-09-455691 · Cited by 176
Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome
Magnasco, A., Ravani, P., Edefonti, A., Murer, L., Ghio, L., Belingheri, M., Benetti, E., Murtas, C., Messina, G., Massella, L., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011080775 · Cited by 174
Burak, K. W., Swain, M. G., Santodomino-Garzon, T., Lee, S. S., Urbanski, S. J., Aspinall, A. I., Coffin, C. S., & Myers, R. P. (2013) · Canadian Journal of Gastroenterology · doi:10.1155/2013/512624 · Cited by 167
van Vollenhoven, R. F., Kinnman, N., Vincent, E., Wax, S., & Bathon, J. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30372 · Cited by 167
Belimumab: A Review in Systemic Lupus Erythematosus
Blair, H. A., & Duggan, S. T. (2018) · Drugs · doi:10.1007/s40265-018-0872-z · Cited by 161
Michel, M., Terriou, L., Roudot‐Thoraval, F., Hamidou, M. A., Ebbo, M., Guenno, G. L., Galicier, L., Audia, S., Royer, B., Morin, A. S., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24570 · Cited by 157
Basu, B., Sander, A., Roy, B., Preussler, S., Barua, S., Mahapatra, T. K. S., & Schaefer, F. S. (2018) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2018.1323 · Cited by 157
Vita, S. D., Quartuccio, L., Séror, R., Salvin, S., Ravaud, P., Fabris, M., Nocturne, G., Gandolfo, S., Isola, M., & Mariette, X. (2015) · Rheumatology · doi:10.1093/rheumatology/kev257 · Cited by 153
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
Komori, M., Lin, Y. C., Cortese, I. C. M., Blake, A., Ohayon, J. M., Cherup, J., Marić, D., Kosa, P. F., Wu, T., & Bielekova, B. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.293 · Cited by 153
Rituximab therapy for HIV-associated Castleman disease
Marcelin, A., Aaron, L., Mateus, C., et al. (2003) · Blood · doi:10.1182/blood-2003-03-0951 · Cited by 152
Jayne, D. R. W., Blockmans, D., Luqmani, R. A., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40802 · Cited by 136
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
Hewett, K., Sanders, D. B., Grove, R. A., Broderick, C. L., Rudo, T. J., Bassiri, A. E., Zvartau-Hind, M. E., Bril, V., On behalf of the BEL115123 Study Group, BEL115123 Study Group, et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005323 · Cited by 131
Adverse reactions to biologic agents and their medical management
Boyman, O., Comte, D., & Spertini, F. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.123 · Cited by 125
Self-citationMease, P. J., Cohen, S. B., GAYLIS, N. B., Chubick, A., Kaell, A. T., Greenwald, M., Agarwal, S. K., YIN, M., & Kelman, A. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090442 · Cited by 125
Uldrick, T. S., Polizzotto, M. N., Aleman, K. O., Wyvill, K. M., Marshall, V. A., Whitby, D., Wang, V., Pittaluga, S., O’Mahony, D., Steinberg, S. M., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586800 · Cited by 124
Genovese, M. C., Kinnman, N., Bourdonnaye, G. D. L., Rossi, C. P., & Tak, P. P. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30373 · Cited by 123
Alexeeva, E. I., Valieva, S. I., Bzarova, T. M., Semikina, E. L., Isaeva, K. B., Lisitsyn, A. O., Denisova, R. V., & Chistyakova, Е. G. (2011) · Clinical Rheumatology · doi:10.1007/s10067-011-1720-7 · Cited by 122
Porter, D. R., Van-Melckebeke, J., Dale, J. E., Messow, C., McConnachie, A., Walker, A., Munro, R., McLaren, J., McRorie, E., Packham, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00380-9 · Cited by 120
EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders
Boyman, O., Kaegi, C., Akdiş, M., Bavbek, S., Bossios, A., Chatzipetrou, A., Eiwegger, T., Firinu, D., Harr, T., Knol, E. F., et al. (2015) · Allergy · doi:10.1111/all.12616 · Cited by 118
Self-citationFisher, B. A., Everett, C., Rout, J., O'Dwyer, J. L., Emery, P., Pitzalis, C., Ng, W., Carr, A., Pease, C. T., Price, E., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212268 · Cited by 115
Arnold, D. M., Heddle, N. M., Carruthers, J., Cook, D. J., Crowther, M. A., Meyer, R. M., Liu, Y., Cook, R. J., McLeod, A. G., MacEachern, J., et al. (2012) · Blood · doi:10.1182/blood-2011-08-374777 · Cited by 111
Lamb, S. E., Mistry, D., Alleyne, S., Atherton, N., Brown, D., Copsey, B., Dosanjh, S., Finnegan, S., Fordham, B., Griffiths, F., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22280 · Cited by 98
Stohl, W., Merrill, J. T., McKay, J. D., LISSE, J. R., Zhong, Z. J., Freimuth, W. W., & Genovese, M. C. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120886 · Cited by 97
Greenwald, M., Shergy, W. J., Kaine, J., Sweetser, M. T., Gilder, K. M., & Linnik, M. D. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30194 · Cited by 96
Li, Z., Mou, W., Lu, G., Cao, J., He, X.-P., Pan, X.-Y., & Xu, K. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0753-z · Cited by 93
Sergott, R. C., Bennett, J. L., Rieckmann, P., Montalbán, X., Mikol, D. D., Freudensprung, U., Plitz, T., & van Beek, J. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.02.019 · Cited by 91
Sun, F., Ladha, S. S., Yang, L., Liu, Q., Shi, S. X.-Y., Su, N., Bomprezzi, R., & Shi, F. (2013) · Muscle & Nerve · doi:10.1002/mus.23951 · Cited by 89
de Menthon, M., Cohen, P., Pagnoux, C., Büchler, M., Sibilia, J., Détrée, F., Gayraud, M., Khellaf, M., Penalba, C., Legallicier, B., et al. (2011) · PubMed · Cited by 78
Xavier Mariette, A., Rouanet, S., Sibilia, J., Combe, B. G., Loët, X. L., Tebib, J. G., Jourdan, R., & Dougados, M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203480 · Cited by 78
Long‐term remission in HIV‐negative patients with multicentric Castleman's disease using rituximab
Ide, M., Kawachi, Y., Izumi, Y., KASAGI, K., & Ogino, T. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00570.x · Cited by 76
Strand, V., Balbir‐Gurman, A., Pavelká, K., Emery, P., Li, N., Yin, M. H., Lehane, P. B., & Agarwal, S. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel358 · Cited by 75
Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Miloslavsky, E. M., Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., Clair, E. W. S., Tchao, N. K., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38788 · Cited by 74
Repeated courses of rituximab in chronic ITP: Three different regimens
Hasan, A. N., Michel, M., Patel, V., Stasi, R., Cunningham–Rundles, S., Leonard, J. P., & Bussel, J. B. (2009) · American Journal of Hematology · doi:10.1002/ajh.21512 · Cited by 67
Rituximab-induced Elimination of Acquired Angioedema Due to C1-Inhibitor Deficiency
Levi, M. M., Hack, C. E., & van Oers, M. H. J. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.018 · Cited by 61
Vital, E. M. J., Dass, S., Buch, M. H., Rawstron, A. C., & Emery, P. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204544 · Cited by 59
Rituximab in psoriatic arthritis: an exploratory evaluation
Jimenez‐Boj, E., Stamm, T., Sadlonova, M., Rovenský, J., Raffayová, H., Leeb, B. F., Machold, K. P., Graninger, W. B., & Smolen, J. S. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201897 · Cited by 50
Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease
Powles, T., Stebbing, J., Montoto, S., Nelson, M. R., Gazzard, B., Orkin, C. M., Webb, A., & Bower, M. (2007) · Blood · doi:10.1182/blood-2007-08-106187 · Cited by 36
Brown, S. T., Everett, C., Naraghi, K., Davies, C., Dawkins, B., Hulme, C. T., McCabe, C. J., Pavitt, S. H., Emery, P., Sharples, L. D., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22340 · Cited by 35
Owczarczyk, K. M., Hellmann, M., Fliedner, G., Rohrs, T., Maizus, K., Passon, D., Hallek, M. J., & RUBBERT, A. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087023 · Cited by 25
YAMADA, M., Akita, M., Nakagawa, T., Takahashi, N., Endo, A., & Yoshida, P. (2013) · Journal of Drug Assessment · doi:10.3109/21556660.2013.792823 · Cited by 10
Cited by
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
Cervia, C., Nilsson, J., Zurbuchen, Y., Valaperti, A., Schreiner, J., Wolfensberger, A., Raeber, M. E., Adamo, S., Weigang, S., Emmenegger, M., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.040 · Cited by 408
Self-citationRecent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies
Mueller, A.-L., Payandeh, Z., Mohammadkhani, N., Mubarak, S. M. H., Zakeri, A., Alagheband Bahrami, A., Brockmueller, A., & Shakibaei, M. (2021) · Cells · doi:10.3390/cells10113017 · Cited by 256
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Mathur, M., Barratt, J., Chacko, B., Chan, T. M., Kooienga, L., Oh, K.-H., Sahay, M., Suzuki, Y., Wong, M. G., Yarbrough, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305635 · Cited by 239
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
Sun, K., Jin, L., Karolová, J., Vorwerk, J., Hailfinger, S., Opalka, B., Zapukhlyak, M., Lenz, G., & Khandanpour, C. (2023) · Cancers · doi:10.3390/cancers15082373 · Cited by 9
Metadata
- Authors
- Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-09-06
- Volume
- 10
- Issue
- 9
- Pages
- 1990-1990
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2965040444
- Cited by
- 260
- References
- 108
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.